Develops anti-cancer stem cell therapeutics
![OncoMed Pharmaceuticals logo](https://files.capedge.com/8-K/0001564590-18-023336/gyttq3xibtvf000001.jpg)
Company profile
Website
CEO
John A. Lewicki
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
383572512
Latest filings (excl ownership)
15-12B
Securities registration termination
3 May 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
8-K
Completion of Acquisition or Disposition of Assets
23 Apr 19
25-NSE
Exchange delisting
23 Apr 19
8-K
Submission of Matters to a Vote of Security Holders
17 Apr 19
Latest ownership filings
SC 13D/A
OncoMed Pharmaceuticals Inc
26 Apr 19
4
Alicia J. Hager
23 Apr 19
4
JONATHAN D ROOT
23 Apr 19
4
JACK W LASERSOHN
23 Apr 19
4
John A. Lewicki
23 Apr 19
4
DEEPIKA PAKIANATHAN
23 Apr 19
4
Yvonne Li
23 Apr 19
4
Robert Stagg
23 Apr 19
4
PERRY A KARSEN
23 Apr 19
SC 13D
OncoMed Pharmaceuticals Inc
15 Mar 19
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|